Objective: The purpose of this trial was to clinically assess the effects of endodontic treatment on glycemic control in patients with type 2 diabetes mellitus (T2DM) and apical periodontitis (AP). Methodology: For present trial, AP+T2DM with patients insulin injection (n=65), AP +T2DM patients with hypoglycaemic agents (n=82), and AP patients without DM (n=86) were enrolled. After demographic characteristics and clinical examination were achieved, root canal treatment (RCT) was performed for each patients. Subjects were followed up at 2-week, 3- and 6-month. At each visit, blood samples were taken, clinical laboratory studies were performed. At 6-month follow-up, Periapical Index (PAI) score was used to assessed the periapical status.Results: A total of 237 subjects who meet the including criteria were allocated in 3 groups and 223 subjects (94.1%) completed cthe treatment and the follow-up assessments. After treatment, taking PAI into consideration, both groups showed significant improvement of AP in each group (P<0.05). Patients had a continued significant lower concentration of fasting plasma glucose (FPG) levels at follow-up except for G1 and G2 (P<0.05). A continued reduction of hemoglobin glycation (HbA1c) was observed in most of time points (P<0.05). Throughout the trial, there are also significant changes of laboratory tests of inflammatory factors in short-term.Conclusion: Endodontic therapy improved AP healing, glycemic control and systemic inflammation in patients with T2DM and/or AP in each group. However, a continued reduction in inflammatory factors and decreasing of HbA1c in short-term did not be observed in this trial.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.